SCI Pharmtech Stock

SCI Pharmtech Current Ratio

The Current Ratio of SCI Pharmtech (4119.TW) as of Aug 8, 2026 is 0.84. In the previous year, Current Ratio was 1.24 — a change of -32.16% (lower).

Current Ratio

0.84

YoY

-32.16%

Last updated:

Current Ratio of SCI Pharmtech is 2026 0.84 . Current Ratio of SCI Pharmtech was 2025 1.24 . It decreases by -32.16% lower compared to the previous year.
Access this data via the Eulerpool API

SCI Pharmtech Stock analysis

What does SCI Pharmtech do? SCI Pharmtech Inc is a leading company in the pharmaceutical industry based in Zhejiang, China. The company was founded in 2003 and has since grown continuously. Today, the company employs over 100 employees and has become a key player in the global supply chain of pharmaceutical raw materials and intermediates. SCI Pharmtech Inc's business model is based on the development and production of high-quality pharmaceutical intermediates and active pharmaceutical ingredients, as well as the manufacturing of custom chemicals. The company specializes in the production and distribution process, offering its customers a comprehensive range of products that meet the highest quality and safety standards. SCI Pharmtech Inc is divided into various divisions, each specializing in specific product categories. The main divisions are API (Active Pharmaceutical Ingredients), intermediates, and custom synthesis. The API division produces active pharmaceutical ingredients for the pharmaceutical industry, which serve as the basis for drug manufacturing. The intermediates division offers pharmaceutical intermediates used in the synthesis of active pharmaceutical ingredients. The custom synthesis division provides tailored synthesis processes for customers in need of specific chemicals or intermediates. SCI Pharmtech Inc's product portfolio includes Acetamidomalonate, Carbamazepine, and Codergocrine Mesylate, among others. The company also offers custom synthesis services, involving complex chemical syntheses and innovative technologies. SCI Pharmtech Inc places great emphasis on quality and safety. The company operates according to international standards, including GMP (Good Manufacturing Practice), ISO (International Standards Organization), and CE (Conformité Européenne). SCI Pharmtech Inc's products undergo stringent quality controls to ensure compliance with the strict regulations of global pharmaceutical regulatory authorities. Another important concern of SCI Pharmtech Inc is sustainability. The company has developed a sustainable business strategy aimed at minimizing its environmental impact and conserving resources. This includes implementing efficient production processes, reducing energy consumption and CO2 emissions, as well as promoting environmental awareness among employees and customers. Overall, SCI Pharmtech Inc is a dynamic and innovative company specializing in the production of pharmaceutical intermediates and active pharmaceutical ingredients. The company takes pride in offering high-quality products that meet the highest quality and safety standards. Through its sustainable business strategy and adherence to international standards, SCI Pharmtech Inc has achieved an excellent reputation in the pharmaceutical industry and strengthened its presence in the global market. SCI Pharmtech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCI Pharmtech stock

Current Ratio of SCI Pharmtech is 0.84 in 2026.

Current Ratio of SCI Pharmtech changed from 1.24 to 0.84, representing a -32.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Ratio SCI Pharmtech since 2006 – with annual values, charts, and detailed analysis.

The Current Ratio measures a company's ability to pay short-term obligations. A ratio above 1 indicates that current assets exceed current liabilities.

Current Ratio = Current Assets / Current Liabilities

A 'good' varies by industry and company stage. On Eulerpool, you can compare Current Ratio's SCI Pharmtech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — SCI Pharmtech

All Key Metrics — SCI Pharmtech